PCI29732, a Bruton’s Tyrosine Kinase Inhibitor, Enhanced the Efficacy of Conventional Chemotherapeutic Agents in ABCG2-Overexpressing Cancer Cells | Zendy

Chunlei Ge | Zendy; Fang Wang | Zendy; Chaochu Cui | Zendy; Xiaodong Su | Zendy; Kenneth K.W. To | Zendy; Xiaokun Wang | Zendy; Hui Zhang | Zendy; Xin Song | Zendy; Liwu Fu | Zendy

Open Access

PCI29732, a Bruton’s Tyrosine Kinase Inhibitor, Enhanced the Efficacy of Conventional Chemotherapeutic Agents in ABCG2-Overexpressing Cancer Cells

Author(s) -

Chunlei Ge,

Fang Wang,

Chaochu Cui,

Xiaodong Su,

Kenneth K.W. To,

Xiaokun Wang,

Hui Zhang,

Xin Song,

Liwu Fu

Publication year - 2018

Publication title -

cellular physiology and biochemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.486

H-Index - 87

eISSN - 1421-9778

pISSN - 1015-8987

DOI - 10.1159/000492647

Subject(s) - abcg2 , rhodamine 123 , flow cytometry , doxorubicin , atp binding cassette transporter , tyrosine kinase inhibitor , pharmacology , western blot , mtt assay , intracellular , cancer cell , efflux , chemistry , microbiology and biotechnology , multiple drug resistance , biology , cell growth , cancer , biochemistry , transporter , chemotherapy , genetics , gene , antibiotics

Multidrug resistance (MDR) induced by the ABC transporter subfamily B member 1 (ABCB1) and subfamilyG member 2 (ABCG2) limits successful cancer chemotherapy and no commercially available MDR modulator is used in the clinic. In the current study, we aimed to investigate the effects of PCI29732 on the enhancement of chemotherapeutic agents.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research